Article

Specific inhibition of HIV-1 protease by boronated porphyrins.

Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco 94143-0446.
Journal of Medicinal Chemistry (Impact Factor: 5.48). 10/1992; 35(18):3426-8. DOI: 10.1021/jm00096a020
Source: PubMed

ABSTRACT ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

0 Bookmarks
 · 
52 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several pterocarpans were synthesized and tested in vitro for activity against HIV. 9-Alkoxy-8-hydroxy-3-methoxypterocarpans exhibited activities in the μM range.
    Bioorganic & Medicinal Chemistry Letters 06/1993; 3(6):1229-1232. DOI:10.1016/S0960-894X(00)80321-2 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of metal-organic complexes is a potentially fruitful approach for the development of novel enzyme inhibitors. They hold the attractive promise of forming stronger attachments with the target by combining the co-ordination ability of metals with the unique stereoelectronic properties of the ligand. We demonstrated that this approach can be successfully used to inhibit the protease of the human immunodeficiency virus (type 1). Several ligands bearing substituents designed to interact with the catalytic site of the enzyme when complexed to Cu2+ were synthesised. The inhibition pattern of the resulting copper(II) complexes was analysed. We showed that the copper(II) complex of N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide (C1) interacts with the active site of the enzyme leading to competitive inhibition. On the other hand, N2-pyridine-amide ligands and oxazinane carboxamide ligand were found to be poor chelators of the cupric ion under the enzymatic assay conditions. In these cases, the observed inhibition was attributed to released cupric ions which react with cysteine residues on the surface of the protease. While unchelated metal cations are not likely to be useful agents, metal chelates such as C1 should be considered as promising lead compounds for the development of targeted drugs.
    Biochemical Pharmacology 05/2002; 63(10):1863-1873. DOI:10.1016/S0006-2952(02)00918-8 · 4.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Aims. Tetrapyrrole substrates and products of heme oxidase are potent inhibitors of HCV replication. It is not clear whether this occurs through primary induction of type I interferon (IFN), inhibition of viral NS3/4A protease, or a combination of these mechanisms. We studied the antiviral actions of tetrapyrroles and their potential influence on type I interferon induction.Methods. Tetrapyrrole effects on NS3/4A protease activity and type I IFN induction were assessed in HCV permissive cells, replicons, or Hek 293 cells transfected with NS3/4A protease. Activation of innate immune signaling was determined after transfection of double strand (ds) surrogate nucleic acid antigens or infection with defined sequence (HCVcc) RNA.Results. Tetrapyrroles failed to directly induce IFN expression at concentrations where they inhibited HCV replication and NS3/4A protease activity. However, tetrapyrroles potently restored IFN induction after attenuation with NS3/4A protease, a process which was accompanied by preservation of the adapter protein MAVS, nuclear localization of IRF3, and augmentation of IFN stimulated gene products.Conclusions. Tetrapyrroles do not directly induce IFN, but dramatically restore type I IFN signaling pathway after attenuation with NS3/4A protease. Tetrapyrroles show immunomodulatory as well as antiprotease activity and are potentially useful for treatment of HCV infection.
    The Journal of Infectious Diseases 07/2013; DOI:10.1093/infdis/jit338 · 5.85 Impact Factor

Full-text (2 Sources)

Download
33 Downloads
Available from
May 27, 2014